David Hughes: Pharmac Chief Medical Officer on the company rethinking decision to end Palivizumab funding
Heather du Plessis-Allan Drive · Newstalk ZB
Audio is streamed directly from the publisher (pdst.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Pharmac is reconsidering whether or not it will continue to fund the RSV drug Palivizumab.
It planned to stop funding, but it's now rethinking that after new information.
Auckland University Associate Professor Jane Alsweiler says the drug is highly effective at keeping babies out of hospital.
Pharmac Chief Medical Officer David Hughes says the past source of funding has dried up.
"Additional Covid-19 pandemic funding from the Government- that funding has ended. And that means Palivizumab needs to be considered through Pharmac's usual process."
LISTEN ABOVE
See omnystudio.com/listener for privacy information.